ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1880

Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis

Alexis Ogdie1, Mark Hwang2, Phani Veeranki3, Alexandria Portelli3, Steven Sison3, Jason Shafrin3, Sofia Pedro4, Esther Yi5 and Kaleb Michaud6, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 3PRECISIONheor, Los Angeles, 4FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), Economics, Health Assessment Questionnaire (HAQ), Health Services Research, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Treatments for ankylosing spondylitis (AS) have been shown to improve patient-reported outcome (PRO) measures in clinical studies; however, healthcare decision makers have limited ability to translate these improvements to healthcare resource utilization (HCRU) or cost savings. Few studies have assessed the economic impact of functional status and patient-reported disease burden in US patients with AS. The purpose of this study was to evaluate the association of PRO measures with HCRU and medical costs in patients with AS from a national US registry.

Methods: FORWARD is a longitudinal observational databank for rheumatic diseases that collects patient-reported data through questionnaires administered every 6 months. Data collected include demographics, clinical characteristics, symptoms, health and functional status, health-related quality of life, and HCRU. This cohort study included adult participants with a diagnosis of AS enrolled in FORWARD between July 2009 and June 2019 who completed ≥ 1 questionnaire between January 2010 and December 2019 and had completed the Health Assessment Questionnaire Disability Index (HAQ-DI) and/or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; added in 2018). Patient demographics, clinical characteristics, and PRO data were collected from the most recent questionnaire. HCRU and medical costs (USD 2019) for all hospitalizations, emergency department (ED) visits, outpatient visits, diagnostic tests, and procedures were assessed for the 6 months prior to survey completion. The relationships between HAQ-DI or BASDAI and HCRU and cost outcomes were assessed using negative binomial regression models for HCRU outcomes and generalized linear models with gamma distribution and log-link function for cost outcomes adjusted for confounders.

Results: A total of 334 patients with AS who completed the HAQ-DI and/or BASDAI questionnaires were included. The mean (SD) age and disease duration were 54.4 (14.3) and 17.5 (12.4) years, respectively. Overall, 61.7% of patients were female and 94.6% were white. The mean (SD) HAQ-DI and BASDAI at time of patients’ most recent survey were 0.9 (0.7) and 3.7 (2.3), respectively (Table 1). HAQ-DI was positively associated with number of hospitalizations, ED visits, outpatient visits, diagnostic tests, and procedures, whereas BASDAI was not associated with HCRU outcomes (Figure 1). Overall mean (SD) direct medical costs for patients with AS were $6520.50 ($12,732.90). There was a significant positive association (coefficient [95% CI]) between medical costs and HAQ-DI (1.76 [1.22-2.55]; P < 0.01), but not with BASDAI (1.05 [0.91-1.22]). Adjusted average medical costs increased with increasing HAQ-DI and BASDAI scores (Figure 2).

Conclusion: Higher HAQ-DI scores were associated with greater HCRU and higher medical costs among patients with AS included in FORWARD, but BASDAI scores were not. These findings indicate that greater functional impairment may impose an increased economic burden compared with other patient-reported aspects of AS throughout the course of the disease. Therapies that effectively improve functional impairment may reduce costs for patients and the healthcare system.


Disclosure: A. Ogdie, AbbVie, 5, Amgen, 2, 5, BMS, 1, Celgene, 1, Corrona, 1, Janssen, 1, Eli Lilly, 1, Novartis, 2, 5, Pfizer, 2, 5, National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2, Rheumatology Research Foundation, 2, National Psoriasis Foundation, 2; M. Hwang, Novartis, 5, University of Texas Health Science Center at Houston (UTHealth) Center of Clinical and Translational Sciences KL2 program, 2; P. Veeranki, PRECISIONheor, 3; A. Portelli, PRECISIONheor, 3; S. Sison, PRECISIONheor, 3; J. Shafrin, PRECISIONheor, 1, 3; S. Pedro, Forward, The National Databank for Rheumatic Diseases, 3; E. Yi, Novartis Pharmaceuticals Corporation, 3; K. Michaud, Rheumatology Research Foundation, 2.

To cite this abstract in AMA style:

Ogdie A, Hwang M, Veeranki P, Portelli A, Sison S, Shafrin J, Pedro S, Yi E, Michaud K. Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/association-of-healthcare-utilization-and-costs-with-patient-reported-outcomes-in-patients-with-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-healthcare-utilization-and-costs-with-patient-reported-outcomes-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology